Search
Vandetanib
go.drugbank.com/drugs/DB05294ApprovedInvestigationalOn April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
Macitentan
go.drugbank.com/drugs/DB08932ApprovedInvestigational[L39105] It was subsequently approved by the FDA in March 2024.[L50622] … [L35890] It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] in part due to its lower risk of hepatotoxicity.
Calcium polycarbophil
go.drugbank.com/drugs/DB14684ApprovedLess gas and bloating compared to psyllium laxative products, but can cause heartburn, and belly cramps. It is insoluble in water, dilute acids, and dilute alkali.
AZD2315
go.drugbank.com/drugs/DB06540ExperimentalThe drug AZD2315, an immunosuppressant developed by AstraZeneca, was in Phase 1 clinical trials for the treatment of rheumatoid arthritis but was discontinued during this phase
Eladocagene exuparvovec
go.drugbank.com/drugs/DB16780ApprovedInvestigational[A253687] It was subsequently approved by the FDA in November 2024.[L51898,L51893] … Eladocagene exuparvovec is infused directly into the brain (putamen) by bilateral intraputaminal infusion in one surgical session.
Insulin icodec
go.drugbank.com/drugs/DB16693ApprovedInvestigational[L50758,A263818] Insulin icodec was approved by Health Canada in March 2024 for the treatment of adult patients with type 1 or 2 diabetes mellitus,[L50758] and was subsequently approved by the EMA in
mRNA-1010
go.drugbank.com/drugs/DB22484ApprovedMFLUSIVA (influenza vaccine, mRNA), also known by its development code mRNA-1010, is a messenger RNA–based vaccine for active immunization against seasonal influenza.
Colistin
go.drugbank.com/drugs/DB00803ApprovedInvestigationalColistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.
Enoximone
go.drugbank.com/drugs/DB04880ApprovedInvestigationalWithdrawnTrials were halted in the U.S., but the drug is used in various countries.
Lomitapide
go.drugbank.com/drugs/DB08827Approved[A7367] Lomitapide was first approved by the FDA in December 2012 and the EMA in July 2013 as an adjunct to a low-fat diet and other lipid-lowering treatments.[A275444, A275446] … A7367] It was developed to address the significant unmet medical need in patients with homozygous familial hypercholesterolemia (HoFH)—an ultra-rare and life-threatening genetic disorder characterized by